WRBY:NYE-Warby Parker Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 25.72

Change

+0.65 (+2.59)%

Market Cap

USD 2.84B

Volume

0.95M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

+0.51 (+0.23%)

USD 66.03B
ALC Alcon AG

+0.70 (+0.82%)

USD 41.92B
RMD ResMed Inc

+1.41 (+0.61%)

USD 34.83B
BAX Baxter International Inc

-0.10 (-0.34%)

USD 16.24B
AVTR Avantor Inc

+0.10 (+0.47%)

USD 14.44B
ATR AptarGroup Inc

+0.83 (+0.52%)

USD 11.39B
TFX Teleflex Incorporated

-0.99 (-0.56%)

USD 8.27B
BLCO Bausch + Lomb Corp

+0.03 (+0.17%)

USD 7.27B
STVN Stevanato Group SpA

-0.02 (-0.10%)

USD 6.36B
INFU InfuSystems Holdings Inc

+0.06 (+0.74%)

USD 0.18B

ETFs Containing WRBY

RETL Direxion Daily Retail Bul.. 1.65 % 1.09 %

+0.21 (+2.08%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 82.41% 100% F 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.41% 100% F 97% N/A
Trailing 12 Months  
Capital Gain 87.05% 100% F 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 87.05% 100% F 97% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.15% 21% F 10% F
Dividend Return -6.15% 21% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 37.15% 58% F 27% F
Risk Adjusted Return -16.55% 16% F 12% F
Market Capitalization 2.84B 36% F 71% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector